- Home
- SACH vs MREO Comparison
SACH vs MREO Comparison
Compare SACH & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SACH | MREO |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United Kingdom |
| Employees | 27 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 52.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SACH | MREO |
|---|---|---|
| Price | $1.06 | $0.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $2.00 | $1.50 |
| AVG Volume (30 Days) | 193.7K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 19.23% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $145.00 | $6,000.20 |
| Revenue Next Year | $6.80 | $34.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.20 |
| 52 Week High | $1.35 | $2.94 |
Technical Indicators
Market Signals| Indicator | SACH | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 36.42 |
| Support Level | $1.05 | $0.32 |
| Resistance Level | $1.12 | $0.42 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 88.83 | 15.80 |
Price Performance
Historical ComparisonAbout SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).